MAXOMAT ®, biosynthetic growth hormone ( DrugBank: Growth hormone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 195 | Noonan syndrome | 1 |
195. Noonan syndrome
Clinical trials : 14 / Drugs : 15 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00452725 (ClinicalTrials.gov) | October 1997 | 23/3/2007 | Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome | Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome | Noonan Syndrome | Drug: MAXOMAT ®, biosynthetic growth hormone | Sanofi | NULL | Completed | 3 Years | 15 Years | Both | 36 | Phase 3 | France |